Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATRIX-2 antithrombotic strategy after PCI in atrial fibrillation
NL-OMON60271Phase 3Recruiting
- Sponsor
- Insel Gruppe
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rivaroxaban in Atrial fibrillation (AFib), atrial flutter (AFL) and coronary arteriosclerosis (2 arms), sponsored by Insel Gruppe. Primary endpoints: Major adverse cardiac or cerebral events (MACCE) and Major or clinically relevant non-major bleeding (MCB). Started Jul 2024; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON60271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60271.